MetaCap

Cue Biopharma (CUE) vs Veru (VERU)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Veru (VERU) has outperformed Cue Biopharma (CUE) over the past year, losing 12.6% versus a loss of 76.8%. Over five years, VERU leads with a -97.5% price change compared with -98.9% for CUE. Cue Biopharma is the larger company by market cap ($34.7 million vs $33.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CUE-76.75%VERU-12.61%
+122%+14%-94%
Nov 21, 20251 yearNov 20, 2026
CUE-99.07%VERU-97.52%
+156%+22%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CUE versus VERU key metrics
MetricCUEVERU
Share price$4.15$1.94
Market cap$34.69M$33.08M
1-day change-7.78%-8.06%
YTD return-54.64%-9.35%
1-year return-76.75%-12.61%
5-year return-98.92%-97.50%
EPS (TTM)$-27.80$-0.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.47M—
Revenue growth (YoY)+195.75%—
Net income (latest FY)$-26.60M$-22.73M
Operating margin-96.67%—
Net margin-96.85%—
52-week high$45.50$7.33
52-week low$2.83$1.93
Distance from 52-week high-90.88%-73.53%
Analyst consensusnonestrong_buy
Avg. price target upside+2020.48%+1223.20%
Average volume567.02K193.35K
Shares outstanding8.36M17.05M
Employees2920
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VERU has outperformed CUE by 64.1 percentage points over the past year.

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Veru

VERU stock →

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

CUE vs VERU FAQ

Which is bigger, Cue Biopharma or Veru?

Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $33.08M for Veru (VERU).

Which stock has performed better over the past year, CUE or VERU?

VERU returned -12.61% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.

Are Cue Biopharma and Veru in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons